Physician profile
Joy Huggins
NPI 1386007672
$1,878.63
in general payments reported to CMS, 2019-2025
15 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $586 · 2022: $375 · 2023: $409 · 2024: $142 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $577.31 | 2021-2025 | Aveir, Jot Dx |
| Novartis Pharmaceuticals Corporation | $413.56 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $323.03 | 2021-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $261.14 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $75.68 | 2021-2024 | Verquvo |
| Sanofi-Aventis U.S. LLC | $48.82 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $45.49 | 2023 | Inpefa |
| Takeda Pharmaceuticals U.S.A., INC. | $22.35 | 2023 | Entyvio |
| Medtronic, INC. | $19.14 | 2021 | |
| Pfizer INC. | $17.73 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $15.89 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.74 | 2022 | |
| Irhythm Technologies, INC. | $14.55 | 2023 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $14.47 | 2023 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $13.73 | 2025 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Huggins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.